Aroa Biosurgery (ASX:ARX): What Does Its CFO Appointment Mean for Expansion?

Sonal Goyal

03 November 2026 06:40 PM AEDT

Aroa Biosurgery (ASX:ARX): What Does Its CFO Appointment Mean for Expansion?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Aroa Biosurgery has appointed Mark Dunwoodie as Chief Financial Officer and Joint Company Secretary, effective 16 November 2026.
Dunwoodie brings more than 25 years of financial, strategic, and operational Leadership experience across listed companies and international financial services.
He joins from NZX-listed Rakon Limited, where he served as Chief Financial Officer and supported the company's growth strategy.
The appointment supports an orderly transition from outgoing CFO James Agnew, who departs at the end of November 2026 after thirteen years with the company.

Aroa Biosurgery Limited (ASX:ARX), a New Zealand-based soft tissue regeneration company, has announced the appointment of Mark Dunwoodie as its new Chief Financial Officer and Joint Company Secretary. Dunwoodie will join the Auckland-headquartered company on 16 November 2026, assuming financial leadership at a point when Aroa is actively scaling its Business internationally, with a primary focus on the United States market.

AROA ECM Technology and the Company's Growth Path

Aroa Biosurgery's products are built around its proprietary AROA ECM technology — a novel extracellular matrix bioscaffold derived from ovine forestomach. The bioscaffold is used in medical and surgical products designed to support the healing of complex wounds and soft tissue reconstruction. Unlike synthetic materials, which provide structural support but limited biological activity, AROA ECM is designed to create an environment that supports the body's own tissue regeneration processes, including the recruitment of cellular populations involved in healing and matrix formation.

The company's product portfolio addresses indications including chronic wound management, reconstructive surgery, and hernia repair — segments that collectively represent a substantial addressable market, particularly in the United States. More than 7.5 million AROA devices have been used globally to date, a Volume that reflects the technology's clinical adoption across a range of surgical and wound care settings.

Distribution in the US market is conducted through a combination of Aroa's own direct sales force and its Partnership with TELABio, Inc. This dual-channel approach provides Aroa with both direct commercial relationships and the broader reach enabled by an established distribution partner with an existing customer base in relevant clinical segments.

Leadership Transition and Incoming CFO Profile

Mark Dunwoodie's appointment follows a comprehensive recruitment process. He brings a career spanning more than 25 years across listed company environments, international financial services, and business advisory roles. Most recently, he served as Chief Financial Officer at Rakon Limited, a New Zealand-listed manufacturer of frequency control products for telecommunications, defence, and space applications, where he contributed to the company's growth strategy and organisational development.

In his new role at Aroa, Dunwoodie will work closely with CEO Brian Ward and the broader leadership team as the company continues to pursue its international growth objectives. His arrival is timed to coincide with the departure of outgoing CFO James Agnew, who will leave the company at the end of November 2026 after thirteen years in the finance leadership role. Agnew's departure follows the release of Aroa's half-year financial results and an accompanying investor roadshow, ensuring a period of overlap and knowledge transfer before the formal transition.

CEO Brian Ward acknowledged both the incoming and outgoing executive, noting Agnew's contribution to establishing the financial, governance, and operational foundations that underpin the company's current position, and expressing confidence in Dunwoodie's ability to support Aroa's next phase of growth.

Key Insights

The appointment of an experienced CFO with a background in listed company finance and growth-phase businesses is a considered step for a company at Aroa's stage. As the company scales internationally — with the US remaining its primary commercial focus — having disciplined financial leadership is an important enabler of that expansion. The orderly transition from a long-serving incumbent CFO to a new appointment with a complementary background reduces the risk of disruption to Investor relations and internal financial governance at a key stage of the company's development. Shareholders will be watching for updates on US commercial progress and the company's trajectory in its direct and partnered distribution channels.

FAQs

Q: What does Aroa Biosurgery do?

A: Aroa Biosurgery develops, manufactures, and sells soft tissue regeneration products based on its proprietary AROA ECM technology — a bioscaffold derived from sheep forestomach — used in wound care and reconstructive surgery.

Q: Who is Mark Dunwoodie?

A: Mark Dunwoodie is the incoming CFO of Aroa Biosurgery. He has over 25 years of financial leadership experience and joins from NZX-listed Rakon Limited, where he served as CFO and supported the company's growth and transformation strategy.

Q: Why is James Agnew leaving?

A: James Agnew is departing Aroa Biosurgery after 13 years as CFO. The timing of his departure, following the half-year results and investor roadshow, has been structured to allow an orderly transition to the incoming CFO.

Q: Where does Aroa sell its products?

A: Aroa's primary market is the United States, where it distributes products through its own direct sales force and through a commercial partnership with TELABio, Inc. The company is headquartered in Auckland, New Zealand.

Q: What is AROA ECM technology?

A: AROA ECM is a bioscaffold derived from ovine (sheep) forestomach tissue. It is designed to provide an environment that supports the body's own tissue regeneration mechanisms in complex wound and soft tissue reconstruction applications.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.